Ticker League

EBITDA for Edwards Lifesciences (EW)

Latest filings through · Reported

Metric

TTM

$1.38B

YoY change

-17.0%

5Y CAGR

+5.9%

Peak year (2022)

$1.96B

EBITDA history chart for Edwards Lifesciences (EW) from 1999 to 2025

Latest: $1.43B

EBITDA growth chart for Edwards Lifesciences (EW) from 1999 to 2025

Latest: -17.0%

EBITDA history table for Edwards Lifesciences (EW) from 1999 to 2025

  • 2025$1.43B-17.0%
  • 2024$1.72B+12.3%
  • 2023$1.53B-21.7%
  • 2022$1.96B+3.7%
  • 2021$1.89B+75.9%
  • 2020$1.07B-17.9%
  • 2019$1.31B+50.0%
  • 2018$872.20M-23.5%
  • 2017$1.14B+37.8%
  • 2016$827.10M+17.1%
  • 2015$706.60M-42.7%
  • 2014$1.23B+109.3%
  • 2013$589.80M+30.3%
  • 2012$452.80M+31.4%
  • 2011$344.70M+5.4%
  • 2010$327.10M-10.6%
  • 2009$365.80M+61.0%
  • 2008$227.20M+6.3%
  • 2007$213.70M-10.8%
  • 2006$239.60M+29.4%
  • 2005$185.20M+85.2%
  • 2004$100.00M-45.7%
  • 2003$184.00M+98.9%
  • 2002$92.50M+14.1%
  • 2001$81.10M-52.0%
  • 2000$169.00M-15.9%
  • 1999$201.00M—

EBITDA values are taken from Edwards Lifesciences's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About EBITDA at Edwards Lifesciences (EW)

According to Edwards Lifesciences's latest reported financial statements, the company's current EBITDA (TTM) is $1.38B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

In 2025, Edwards Lifesciences (EW) EBITDA totalled $1.43B – declined 17.0% year-over-year.

Edwards Lifesciences EBITDA has grown on net over the period, with a +5.9% compound annual growth rate over 2020–2025 (5 years).

Edwards Lifesciences EBITDA peaked at $1.96B in 2022; the latest annual figure is $1.43B in 2025 (27.1% below peak).

Across the available history, EBITDA reached its high of $1.96B in 2022 and its low of $81.10M in 2001.

Edwards Lifesciences EBITDA by Year

Edwards Lifesciences EBITDA 2025: $1.43B

In 2025, Edwards Lifesciences reported EBITDA of $1.43B, declined 17.0% below 2024.

Edwards Lifesciences EBITDA 2024: $1.72B

Edwards Lifesciences EBITDA in 2024 was $1.72B, grew 12.3% from 2023.

Edwards Lifesciences EBITDA 2023: $1.53B

2023's EBITDA for Edwards Lifesciences came in at $1.53B, declined 21.7% below 2022.

Edwards Lifesciences EBITDA 2022: $1.96B

Edwards Lifesciences posted EBITDA of $1.96B in 2022, edged up 3.7% from 2021. This figure represents the highest annual value in the available history.

Edwards Lifesciences EBITDA 2021: $1.89B

Edwards Lifesciences EBITDA in 2021 was $1.89B.

See more financial history for Edwards Lifesciences (EW).

Sector peers by EBITDA

Healthcare peers of Edwards Lifesciences (EW), ranked by their latest EBITDA

Frequently asked questions

Edwards Lifesciences (EW) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview